Kefzol

Quick links to important sections

Kefzol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kefzol

Quick Facts

Property Description
Active ingredient Cefazolin sodium
Form Sterile powder for injection
Pharmacological class beta-Lactam antibiotic, First-generation cephalosporin
General purpose Combating and preventing bacterial infections
Origin Semisynthetic

Kefzol is a prescription-only medicine that functions as a semisynthetic beta-Lactam antibiotic used to combat and prevent bacterial infections. Its active component is Cefazolin sodium, which places it within the specific group of first-generation cephalosporins.


What Type of Antibiotic is Kefzol (Cefazolin)?

Kefzol's active ingredient, Cefazolin sodium, is classified within the pharmacological class of beta-Lactam antibiotics, a category of drugs defined by their common mechanism of action against the bacterial cell wall. As a semisynthetic compound, Cefazolin is chemically derived to enhance its potency and stability compared to naturally occurring analogues. The designation as a first-generation cephalosporin distinguishes it by its established spectrum of antimicrobial activity, which is widely clinically recognized and supported by pharmacological studies.


Composition and Format: Why is Kefzol Supplied as a Powder?

Kefzol is supplied as a sterile powder for injection, which is a specialized dosage form designed for immediate reconstitution into an injectable solution for patient use. This powder format ensures the drug's long-term chemical stability and integrity until the time of administration, a critical feature for inventory management. It is a single-ingredient product, containing only Cefazolin sodium, and requires an aqueous diluent or base/vehicle before being administered via the parenteral route, specifically through Intramuscular administration (IM) or Intravenous administration (IV).


Kefzol's General Purpose: What Does This Medicine Help Achieve?

The general purpose of Kefzol is to achieve rapid microbial control by acting as a powerful bactericidal agent that actively kills susceptible bacteria in the body. Cefazolin achieves this by causing the inhibition of bacterial cell wall synthesis, destroying the protective layer of the microbe. This action allows the medicine to be used both for treating established bacterial infections and, critically, for surgical prophylaxis—serving as a standard preventative measure to help guard against the development of infections during and immediately following medical procedures.

Regulatory References

  1. NIH DailyMed Label for Cefazolin

What side effects are possible with Kefzol ?

Possible Side Effects and Safety Information

The safety profile of Cefazolin sodium (Kefzol) is defined by adverse reactions classified by official government regulatory documents based on frequency and the physiological system affected.

Adverse Reactions by Frequency and System

Classification Examples of Officially Documented Adverse Reactions
Common Gastrointestinal disorders such as nausea, vomiting, and diarrhea; and General disorders including pain or inflammation (phlebitis) at the injection site.
Uncommon / Rare Skin disorders like rash and pruritus; transient increases in hepatic enzymes; and Blood and lymphatic system disorders such as leukopenia and eosinophilia.

Serious Adverse Reactions and Safety Patterns

Certain reactions are documented as serious in regulatory labeling. These include severe, immediate allergic responses such as anaphylaxis. Reactions affecting the Gastrointestinal system may include pseudomembranous colitis, which is a severe form of diarrhea associated with C. difficile overgrowth. Additionally, high doses or use in patients with renal impairment are officially associated with a higher risk of Nervous system disorders, specifically seizures.

Population-Specific Safety Considerations

The official prescribing information notes that Cefazolin is generally contraindicated in individuals with a known severe, immediate hypersensitivity reaction to cephalosporins or other beta-Lactam antibiotics. Caution is also specifically noted for patients with pre-existing renal impairment due to the increased potential for adverse effects on the central nervous system.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific signs and required actions in the event of an overdose with Cefazolin sodium (Kefzol).

Documented Overdose Presentations

Overdosage is documented to present with signs such as headaches, dizziness, and paresthesias (tingling). Local reactions at the injection site, including pain, inflammation, and phlebitis, may also occur. The most serious officially documented outcome of overdose is severe CNS toxicity, manifesting as encephalopathy and potentially seizures (fits).

Overdose Risk and Management

Classification Detail Official Regulatory Statement
Population-Specific Risk The risk of seizures is heightened in patients with renal impairment (kidney dysfunction) due to the likelihood of drug accumulation.
Antidote Information No specific antidote is known; management involves supportive treatment and meticulous monitoring.
Procedural Action If seizures occur, the medicine must be discontinued promptly, and anticonvulsant therapy may be administered if clinically indicated.

When Immediate Medical Help is Required

Immediate medical attention is required for suspected overdose. Official guidance mandates calling emergency services (911) if the patient has collapsed, had a seizure, is experiencing trouble breathing, or can't be awakened. Additionally, contact the Poison Control Helpline for guidance.

Therapeutic Uses of Kefzol

What Kefzol Treats: Main Uses and Benefits

Kefzol is applied across domains where additional symptomatic support is needed, primarily for treating established bacterial infections that cause symptoms related to systemic imbalance and localized discomfort. This generally includes infections of the lungs (pneumonia), urinary tract, skin and soft tissues (like cellulitis), and bone and joints. This medicine is also relevant for managing severe, life-threatening conditions such as septicemia (bloodstream infection) and bacterial endocarditis (heart valve infection); it is commonly used across conditions presenting with acute episodes.

The medication helps address symptom clusters that may become intense or disruptive, such as high fever, chills, pain, and swelling at the infection site. Kefzol is commonly used for perioperative prophylaxis—an application that may assist with reducing the potential for infections to develop during and immediately after surgical procedures. This preventative use helps maintain a sense of stability when symptoms are more noticeable, assisting with reducing the potential for severe complications that could otherwise contribute to functional strain and interfere with recovery.


Quick Fact: Relief for Systemic Discomfort Kefzol is commonly used to help manage symptoms related to systemic imbalance, such as fever and chills, alongside localized signs of inflammatory or irritative states caused by susceptible bacterial pathogens.

Eligibility and Restrictions for Use

Kefzol (cefazolin) is an antibacterial drug whose use is defined by specific population constraints documented in official regulatory labeling.

Contraindicated Populations

The drug is absolutely contraindicated for patients with a known history of hypersensitivity to cefazolin or to any antibiotic in the cephalosporin class. Caution is mandatory for individuals with a history of penicillin allergy, as cross-hypersensitivity with cefazolin has been documented.

Age and Organ Function Eligibility

Population Group Eligibility Status
Infants under 1 month Use is not established; generally not recommended.
Renal Impairment Use is restricted; dosage must be significantly reduced according to creatinine clearance to prevent drug accumulation and potential seizures.
Pregnancy Use is conditional; only if clearly needed, as safety has not been fully established.
Breastfeeding Use with caution; low levels are found in breast milk, though not typically expected to cause harm.

Use is established for most adults and children one month of age and older. The drug must not be administered via the intrathecal (spinal) route, as this is associated with severe CNS toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents define Kefzol’s interaction profile based on pharmacokinetic effects, pharmacodynamic risks, and administration restrictions. All statements reflect information explicitly documented by government health authorities.

Interactions Affecting Drug Exposure and Organ Risk

Interacting Substance Official Regulatory Outcome Classification
Probenecid Inhibits renal tubular secretion, resulting in increased and more prolonged Cefazolin blood levels. Pharmacokinetic
Oral Anticoagulants Associated with a fall in prothrombin activity, increasing the risk of bleeding. This risk is specifically noted in patients with renal impairment, hepatic impairment, or a poor nutritional state. Pharmacodynamic
Nephrotoxic Agents Co-administration may result in an increased risk of nephrotoxicity due to additive organ toxicity. Pharmacodynamic

Administration Restrictions and Diagnostic Interference

Co-administration with live bacterial vaccines (such as BCG and Typhoid vaccines) is formally restricted as a contraindicated combination due to the risk of pharmacodynamic antagonism. The use of these medicines requires temporal separation.

Cefazolin is also documented to interfere with specific laboratory procedures. It may cause a false-positive reaction for glucose in the urine when tests utilizing copper-reduction methods (e.g., CLINITEST) are employed. Furthermore, the medicine is officially documented to cause positive direct and indirect antiglobulin (Coombs') tests.

Mechanism of Action

The action of Kefzol (Cefazolin) is defined by its precise and targeted intervention in the process of bacterial cell wall construction, which produces a bactericidal effect on susceptible microbes.

Irreversible Inhibition of Penicillin-Binding Proteins (PBPs)

Cefazolin functions as an irreversible inhibitor that permanently disables Penicillin-Binding Proteins (PBPs). These bacterial enzymes catalyze the final cross-linking steps of the cell wall. The drug's covalent binding to the active site of PBPs initiates the breakdown of the microbe's structural integrity.

Cascade of Osmotic Destruction and Lysis

Following PBP inhibition, Cefazolin prevents the necessary peptidoglycan cross-linking. This structural failure causes the bacterial cell to become highly osmotically unstable and triggers the activation of self-degrading enzymes. The resulting cellular collapse and rupture (lysis) defines the drug's bactericidal physiological effect.

Constraints and Mechanism Limitations

The mechanism's action is constrained by bacterial defense strategies, notably the production of beta-Lactamase enzymes that inactivate the drug. Efficacy is also restricted against bacteria that express modified target PBPs, which prevents adequate covalent bond formation and nullifies the disruptive cascade.

Dosage and Administration Information

How Kefzol is Used

Kefzol (Cefazolin) is administered according to strict dosage and administration guidelines. This medicine is a sterile powder for injection that must be prepared and delivered by a healthcare professional in a specialized setting.


Official Administration Guidelines

Feature Official Instruction
Route of Administration Primarily Intravenous (IV) injection or infusion; some formulations allow Intramuscular (IM) injection.
Preparation Requirements Sterile powder must be aseptically reconstituted and typically further diluted with a compatible solution for IV infusion. Premixed solutions require thawing and visual inspection for particulate matter.
IV Infusion Rate Administer the dose intravenously over approximately 30 minutes.

Standard Dosing and Scheduling

Dosages are highly dependent on the type of use and the patient’s condition. Doses for adult patients with normal kidney function (Creatinine Clearance ge 55 mL/min) fall within established ranges:

  • Moderate Infections: 500 mg to 1 gram (g), typically given every 6 to 8 hours (q6-8h).
  • Severe, Life-Threatening Infections: 1 g to 1.5 g, given every 6 hours (q6h). Doses up to 12 grams per day may be used in rare instances.
  • Perioperative Prophylaxis: The initial dose (1 g to 2 g) is given 1/2 hour to 1 hour prior to the start of surgery, followed by supplementary doses every 6 to 8 hours for up to 24 hours postoperatively.

If a dose is missed, patients are generally instructed to use the missed dose as soon as they remember; however, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking a double dose.


Population-Specific Use Rules

Dosage adjustment is required for adult patients whose Creatinine Clearance (CLcr) is less than 55 mL/min due to reduced kidney function. The dose or the dosing interval must be modified according to the degree of impairment. For pediatric patients (1 month and older), dosing is calculated based on body weight (mg/kg per day) and divided into equal doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kefzol


Evidence for Use in Surgical Infection Prevention (Prophylaxis)

Cefazolin's use in infection prevention studies (prophylaxis) was studied for this application in a large body of evidence. This evidence includes Randomized Controlled Trials (RCTs) and large-scale systematic reviews that research examined its use before and during various operations. Studies monitored outcomes such as the incidence of Surgical Site Infections (SSIs), hospital readmission rates, and the need for further procedures.

Findings describe patterns observed in the studies where infection rates was observed in groups receiving Cefazolin, sometimes compared to different agents or no intervention. Long-term effects are not fully established beyond the typical 90-day post-operative period for tracking SSIs. Data for certain groups remain insufficient, particularly concerning the relationship between dosing and measured drug concentration in the tissues of patients with high body weight (obesity).


Evidence for Treatment of Established Infections

This block will summarize the research that has explored Cefazolin's use in treating skin and soft tissue infections and bone and joint infections. It will detail the mix of comparative clinical trials and observational cohort studies used in research exploring how symptoms change over time, focusing on how researchers defined and measured changes in status and recurrence.

Evidence for Use in Bone and Joint Infections

For infections of the bone and joints, the research primarily relies on prospective and retrospective observational cohort studies. Studies monitored outcomes related to physical discomfort over extended periods, often following patients for a year or more. The outcomes measured included research assessing measures of clinical and microbial status and the frequency of recurrence or relapse over time.

Evidence for Use in Infective Endocarditis

Cefazolin was studied for the treatment of severe conditions like Methicillin-Susceptible Staphylococcus aureus (MSSA) infective endocarditis. The evidence here is unique: comparative evidence is lacking from high-level RCTs for Cefazolin against certain other agents used for this condition. Instead, research describes patterns from systematic reviews and observational cohort studies.


What is Still Uncertain About Kefzol Research

Despite decades of use, evidence highlights what is known — and what is still uncertain about Cefazolin. One key limitation is the comparative evidence is lacking from recent, high-quality Randomized Controlled Trials (RCTs) against newer antibiotic agents. Data are still emerging regarding the relationship between dosing and measured concentration for certain patients, such as those with extreme body weight, where research is ongoing to evaluate drug concentrations in the relevant tissues.

Frequently Asked Questions (FAQ)

Common questions about Kefzol (FAQ)


Q: Does Kefzol cause drowsiness or affect my ability to drive?

A: Regulatory documents mention that Cefazolin may be associated with central nervous system (CNS) effects, which can include symptoms like dizziness and somnolence (drowsiness). A healthcare provider can offer guidance regarding activities like driving while experiencing these effects. Official safety information also notes that high doses, particularly in people with kidney issues, may carry an increased risk of seizures.


Q: What food or drinks should be avoided while being treated with Kefzol?

A: The official drug label for Cefazolin does not specifically list any required restrictions regarding food or drinks. Information regarding the use of alcohol or any specific dietary restrictions should be reviewed with a healthcare professional.


Q: Can people with a history of kidney problems use Kefzol?

A: People with reduced kidney function can be treated with Cefazolin. However, for these individuals, official prescribing information indicates that a modification to the administered dose is necessary. This step helps prevent the drug from accumulating in the body, which could otherwise increase the potential for side effects.


Q: Is Kefzol safe to use during pregnancy?

A: Cefazolin is known to cross the placenta. Official information states the drug should only be used during pregnancy if it is clearly needed, where the therapeutic benefit is judged to outweigh the potential risk. Controlled safety data on human pregnancy are not fully available.


Q: What risk does Kefzol pose to a nursing baby?

A: Cefazolin is known to be excreted into human milk in small amounts. These low levels are generally not expected to cause harmful effects to the nursing infant. The possibility that the drug could alter the infant's gut flora, potentially causing symptoms like diarrhea or oral thrush, is noted in the information.


Q: What should I tell my healthcare provider before receiving Kefzol?

A: Official information details specific medical history that should be reviewed with a healthcare provider prior to receiving Cefazolin. This includes any history of allergy to Cefazolin, any cephalosporin, or any penicillin-type antibiotic, as well as any history of kidney disease, liver disease, colitis, or seizure disorders.


Q: Why is Kefzol sometimes used before surgery?

A: Cefazolin is indicated for perioperative prophylaxis, which is the prevention of infection during and immediately after a surgical procedure. It is administered to reduce the risk of certain infections that might otherwise develop following classified contaminated or potentially contaminated surgical procedures.


Q: Does Kefzol affect the results of any common medical lab tests?

A: Yes, Cefazolin is officially documented to interfere with specific laboratory procedures. It can cause a false-positive reaction for glucose in the urine when certain copper-reduction tests are used. It may also lead to a positive result on both the direct and indirect Coombs' test, which checks for certain antibodies in the blood.


Q: Do official documents mention any potential for Kefzol to interact with vitamins or supplements?

A: The official drug label primarily focuses on interactions with other prescription medications and does not detail interactions with most common vitamins or supplements. However, it notes that patients with a poor nutritional state may have an increased risk of bleeding when taking anticoagulants alongside Cefazolin. Guidance on vitamins and supplements should be sought from a healthcare professional.


Q: Is Kefzol considered a penicillin-like antibiotic?

A: Cefazolin is a cephalosporin, which belongs to the same general class of drugs—the beta-lactam antibiotics—as penicillin. For this reason, official warnings note that a history of penicillin allergy is important to disclose, as there is documented cross-hypersensitivity between these two groups of medicines.


Q: How quickly does Kefzol typically start working after I receive it?

A: The time it takes for Cefazolin to achieve effective levels in the body is quite fast. Official pharmacology data indicates that the drug reaches its peak concentration in the bloodstream approximately 5 minutes following an intravenous (IV) injection.


Q: How long does the effect of Kefzol last in the body?

A: In patients with normal kidney function, the official clinical data states that Cefazolin has a serum half-life of about 1.8 to 2.0 hours following administration. This means that about half of the drug concentration is cleared from the bloodstream within that time, and approximately 70% to 80% of the dose is excreted within 24 hours.


Q: Is it normal to feel tired while recovering from an infection treated with Kefzol?

A: Official reports of adverse reactions mention that tiredness, weakness, and malaise (a general feeling of being unwell) have been reported, although they are uncommon or rare. It is important to note that general fatigue is often a part of the body's natural recovery process from a bacterial infection itself.


Q: Can children or infants be treated with Kefzol?

A: Yes, Cefazolin is indicated for use in pediatric patients one month of age and older. Dosing for children is carefully calculated based on their body weight. Use in infants under one month old is generally not established.


Q: Are there any known issues with Kefzol and alcohol consumption?

A: The official regulatory label does not specifically mention a direct interaction between Cefazolin and alcohol. The use of alcohol while being treated with any antibiotic is typically a subject for discussion with a healthcare professional.


Q: Do studies suggest that Kefzol is effective for bone and joint infections?

A: Yes, Cefazolin is officially indicated for the treatment of bone and joint infections. This is specifically for infections caused by susceptible Staphylococcus aureus (S. aureus), a common type of bacteria found in these conditions.


Q: Are there any specific safety warnings related to Kefzol in older adults?

A: Safety and effectiveness in older adults are generally similar to those in younger adults. However, because older adults are more likely to have reduced kidney function, adjustment of the dose may be necessary. This adjustment is crucial to prevent the drug from accumulating, which can lead to adverse effects.


Q: Is Kefzol known to interact with birth control pills?

A: Official information states that antibiotics, including Cefazolin, may potentially interfere with the effectiveness of estrogen-containing birth control in some people. Patients are encouraged to review this potential interaction with their healthcare provider, as an alternative or additional form of birth control may be considered during treatment.


Q: Does Kefzol affect the natural balance of bacteria in the body?

A: Yes, Cefazolin is known to affect the body's natural bacterial balance. By targeting harmful bacteria, it also alters the normal flora of the colon, which can lead to the overgrowth of other organisms. This alteration is the cause of Clostridioides difficile-associated diarrhea (CDAD), a severe form of diarrhea.


Q: Is Kefzol a broad-spectrum or narrow-spectrum antibiotic?

A: Cefazolin is considered active against a range of bacteria. The official label specifies that it is effective against various Gram-positive bacteria (like Staphylococcus and Streptococcus) and certain Gram-negative bacteria (like E. coli and P. mirabilis), classifying it as having a moderate spectrum of activity.


Q: Are there research papers examining Kefzol's use in prosthetic joint infections?

A: Cefazolin is officially indicated for the treatment of bone and joint infections. While the official label does not specify research on the exact subset of prosthetic joint infections, this condition falls within its indicated area of use.


Q: What research themes are commonly explored regarding Kefzol?

A: Regulatory indications demonstrate that Cefazolin research centers on several key areas. These common themes include the treatment and prevention of infections in the Respiratory Tract, Urinary Tract, Skin, Bones and Joints, and its critical use in Perioperative Prophylaxis (infection prevention before surgery).


Q: Is Kefzol used in dental procedures to prevent infection?

A: Cefazolin is officially indicated for perioperative prophylaxis for procedures classified as contaminated or potentially contaminated. While the official label does not specifically mention dental procedures, this is the general category of use for which it is prescribed.


Q: Does Kefzol require special monitoring once administered?

A: Yes, certain patients require careful monitoring. For example, individuals with impaired kidney function should be closely observed to prevent drug accumulation and serious side effects. Patients who are at risk for bleeding (e.g., those on blood thinners) may require monitoring of their prothrombin time, which measures how quickly blood clots.


Q: Can Kefzol cause changes in a person's mood or behavior?

A: Official adverse reaction reports mention that Cefazolin can cause Central Nervous System (CNS) effects. These effects may include changes in mental status such as disorientation and memory loss, as well as hyperactivity. If such symptoms are observed, the medicine may need to be discontinued.


Q: Is it possible for Kefzol to cause an infection, rather than treat one?

A: Yes. Official warnings state that prolonged use of Cefazolin or any antibiotic may sometimes result in the overgrowth of non-susceptible organisms. This change in the body's microbial balance can lead to a secondary infection, often called a superinfection.


Q: Is there any public research on the long-term effects of Kefzol?

A: The official nonclinical data states that long-term animal studies have not been performed to determine the potential for Cefazolin to cause cancer (carcinogenic potential) or genetic mutations (mutagenicity). Specific data on long-term effects are thus limited in official documentation.


Q: Can Kefzol be used to treat urinary tract infections?

A: Yes, according to the official indications, Cefazolin is used for the treatment of urinary tract infections. This use is specifically for infections caused by susceptible organisms like E. coli, P. mirabilis, and Klebsiella species.


Q: What type of bacteria is Kefzol most effective against?

A: Cefazolin is most effective against a range of Gram-positive bacteria, which include common types like Staphylococcus aureus (S. aureus) and Streptococcus pyogenes. It is also indicated for use against certain Gram-negative bacteria, such as E. coli and Klebsiella species.

How should Kefzol be stored and disposed of?

How to Store and Dispose of Kefzol?

The storage and disposal of Kefzol (Cefazolin sodium) must follow strict regulatory guidelines to maintain drug stability and ensure safety.

Storage Condition Requirement Stability Limit (Reconstituted)
Dry Powder Vials Store at Controlled Room Temperature (20 to 25 C) and protect from light. ---
Reconstituted Solution Store under refrigeration (2 to 8 C or 36 to 46 F). Up to 3 to 10 days (varies by product type/concentration).

All unused portions of the reconstituted solution must be discarded after the stated time limits. Do not refreeze thawed premixed products, and avoid using methods like water baths for thawing. The medication must be kept in its tightly closed container, out of the sight and reach of children. For disposal, unused or expired Kefzol should not be flushed down the toilet. Instead, the official instructions recommend utilizing a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kefzol  found in:

A-Z Index: